Trial Profile
A trial investigating ORC-13661 in healthy volunteers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs ORC-13661 (Primary)
- Indications Hearing loss
- Focus Adverse reactions; First in man; Pharmacokinetics
- 27 Sep 2018 Status changed from planning to recruiting, as reported in a Decibel Therapeutics media release.
- 07 Feb 2018 New trial record
- 05 Feb 2018 According to an Oricula Therapeutics media release, the US FDA has granted permission to begin volunteer human testing of ORC-13661.